TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32450908
Drug: Mecobalamin tablets
Normalized name: mecobalamin Oral Tablet
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mecobalamin tablets (Control)
Study: 37309006
Drug: Compassion-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassion-focused therapy (CFT)
Study: 32160301
Drug: H. P.
Normalized name: Hydrocortisone Phosphate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H. P. Acthar gel (repository corticotropin injection)
Study: 32489675
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity Intervention for Loneliness (PAIL) - once-weekly group walk and health education workshop up to 90 min per session for 12 weeks.
Study: 35069013
Drug: Augmented Mindfulness-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented Mindfulness-Based Cognitive Therapy (MBCT) combined with pharmacotherapy
Study: 35069013
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment dominated by pharmacotherapy (Control group)
Study: 33284989
Drug: Text-messaging support,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text-messaging support, e-cigarettes, cognitive behavioral therapy
Study: 32441198
Drug: Co-supplementation (50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-supplementation (50,000 IU vitamin D weekly + two omega-3 fatty acid capsules daily)
Study: 32441198
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid (two omega-3 fatty acid capsules daily + vitamin D placebo weekly)
Study: 32441198
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (50,000 IU vitamin D weekly + omega-3 placebo daily)
Study: 32441198
Drug: Control (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (vitamin D placebo weekly + two omega-3 placebo capsules daily)
Study: 33606914
Drug: Y14 (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y14 (extended-release peptide YY analogue), multiple doses between 9 and 36 mg, given at 7- to 14-day intervals over 28 days.
Study: 35042047
Drug: Intrapartum nipple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapartum nipple stimulation therapy
Study: 35770374
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis administration
Study: 33249273
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg) + L-arginine (1.5 g)
Study: 34559686
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil applied to abdomens twice a day
Study: 36110080
Drug: Mtwo root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mtwo root canal preparation method modified by Mtwo machine nickel‐titanium file
Study: 36110080
Drug: Modified Mtwo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Mtwo preparation method with synchronous root canal length measurement
Study: 33920725
Drug: Selenium yeast
Normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium yeast (200 µg/day) and coenzyme Q10 (200 mg/day)
Study: 35090544
Drug: Barkley program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barkley program (treatment-as-usual)
Study: 33630453
Drug: Intravenous Local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Local Anesthetic (IVL)
Study: 36148741
Drug: EPA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA supplementation (3 g/day)
Study: 36148741
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (3 g/day)
Study: 32843251
Drug: Nonextraction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonextraction therapy
Study: 32448345
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered remdesivir for 10 days
Study: 36058795
Drug: CCHFV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCHFV vaccine trial designed to capture infection as a trial endpoint
Study: 36058795
Drug: CCHFV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCHFV vaccine trial designed to capture clinical case as a trial endpoint
Study: 36058795
Drug: CCHFV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCHFV vaccine trial
Study: 36058795
Drug: Increased expected
Normalized name: docosahexaenoic acid Oral Capsule [Expecta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased expected vaccine efficacy > 60%
Study: 36106146
Drug: Glutamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.3 g kg FFM−1)
Study: 34132024
Drug: Topical C.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical C. rotundus oil
Study: 37208998
Drug: Dapagliflozin, 10
Normalized name: Dapagliflozin, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin, 10 mg, once daily
Study: 32666599
Drug: Transplanted human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transplanted human fetal ganglionic eminence (treatment group)
Study: 32472172
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravitreal ranibizumab and panretinal photocoagulation (PRP) (n=24)
Study: 32472172
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (ranibizumab alone and combination)
Study: 36472134
Drug: lemborexant 5
Normalized name: lemborexant 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lemborexant 5 mg
Study: 32236507
Drug: Imatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (400 mg/d) for 2 years
Study: 36172885
Drug: 70 g
Normalized name: alcohol .70 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 g mycoprotein (MYC; 31.4 g protein, 2.5 g leucine; n=12)
Study: 36172885
Drug: 38.2 g
Normalized name: nut.tx,metabolic dis,methio-fr 38.2 gram-376 kcal/100 gram ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38.2 g of a protein concentrate obtained from mycoprotein (PCM; 28.0 g protein, 2.5 g leucine; n=12)
Study: 34008421
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or Clopidogrel (Control)
Study: 33151500
Drug: Bumetanide oral
Normalized name: bumetanide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide oral liquid formulation
Study: 32387408
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 80 μg delivered via Breezhaler®
Study: 32387408
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 320 μg delivered via Breezhaler®
Study: 32387408
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 80 μg and 320 μg delivered via Breezhaler®
Study: 32387408
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 200 μg and 800 μg delivered via Twisthaler®
Study: 32124817
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anesthesia (TIVA) with 45° head rotation
Study: 32124817
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anesthesia (TIVA) with no head rotation
Study: 33687555
Drug: MINST +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MINST + NaOCl gel
Study: 32394686
Drug: del Nido
Normalized name: Del Nido Cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: del Nido solution (DNS)
Study: 32394686
Drug: cold blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: cold blood cardioplegia solution (CBCS)
Study: 33617294
Drug: DECTA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DECTA with 50% reduced iodine dose (300 mgI/kg)
Study: 33617294
Drug: SECTA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SECTA with standard iodine dose (600 mgI/kg)
Study: 33965769
Drug: Nitrate exposure
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate exposure >25 mg/L (preconception)
Study: 33965769
Drug: Nitrate exposure
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate exposure >25 mg/L (prenatal)
Study: 33965769
Drug: Nitrate exposure
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate exposure >25 mg/L (postnatal)
Study: 38340127
Drug: Crisaborole ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole ointment, 2%
Study: 32642971
Drug: PGX (15–20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGX (15–20 g/day)
Study: 32642971
Drug: Placebo (isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isocaloric rice flour, 6.4–8.6 g/day)
Study: 32830200
Drug: Gemcitabine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine treatment (n = 71)
Study: 32830200
Drug: Non-gemcitabine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-gemcitabine treatment (n = 59)
Study: 37779541
Drug: GSK3772847 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3772847 (10 mg/kg intravenous)
Study: 32044419
Drug: Paclitaxel/cisplatin (PacCis)‐CRT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel/cisplatin (PacCis)‐CRT; paclitaxel 20 mg/m2 on days 2, 5, 8, 11 and 25, 30, 33, 36; cisplatin 20 mg/m2, days 1‐4 and 29‐32; RT to a total dose of 63.6 Gy
Study: 32044419
Drug: Fluorouracil/cisplatin (CisFU)‐CRT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil/cisplatin (CisFU)‐CRT; fluorouracil 600 mg/m2; cisplatin 20 mg/m2, days 1‐5 and 29‐33; RT: 70.6 Gy
Study: 35251584
Drug: Subanaesthetic dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanaesthetic dose of ketamine
Study: 32815661
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (pharmacological SBP reduction to <120 mm Hg upon enrollment)
Study: 32815661
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (clinical follow-up till SBP goes above 140 mm Hg and then starting medications to keep SBP <140 mm Hg)
Study: 34416229
Drug: Low-dose GSNO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GSNO (up to 20 nmol/kg/min)
Study: 34416229
Drug: High-dose GSNO
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GSNO (up to 60 nmol/kg/min)
Study: 35287112
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day anthocyanin-rich blackcurrant extract for 7 days
Study: 32324307
Drug: Smartphone-enabled home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-enabled home-based exercise therapy (HBET) with daily exercise reminders and educational content, weekly phone-based coaching sessions.
Study: 33848805
Drug: Control (ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ADT plus chemotherapy)
Study: 37802824
Drug: Clinical syndrome-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical syndrome-based medicine incorporating optimal clinical experience
Study: 37802824
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) practices
Study: 32515696
Drug: Intracranial mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracranial mechanical thrombectomy plus internal carotid artery stenting (and at least one antiplatelet therapy)
Study: 35780799
Drug: Non‐typeable Haemophilus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐typeable Haemophilus influenzae–Moraxella catarrhalis vaccine
Study: 34123370
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg) evening administration
Study: 34123370
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg) morning administration
Study: 34510212
Drug: Exogenous medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous medical food ketone formulation (KF)
Study: 37336228
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg
Study: 35357406
Drug: Posturography-assisted vestibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posturography-assisted vestibular retraining (12 twice-weekly sessions)
Study: 34338481
Drug: Folitime® (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folitime® (225 IU/day for 5 days, followed by dose adaptation up to 450 IU/day)
Study: 34338481
Drug: Gonal-f® (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonal-f® (225 IU/day for 5 days, followed by dose adaptation up to 450 IU/day)
Study: 35623659
Drug: Sintilimab 200
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200 mg administered intravenously on day 1 every 3 weeks and anlotinib 12 mg administered on days 1-14 in a 21-day cycle.
Study: 35026180
Drug: NTHi-Mcat vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTHi-Mcat vaccine
Study: 33592844
Drug: Mesalazine enteric-coated
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine enteric-coated tablets combined with Kangfuxin Liquid (KFX) enema
Study: 33592844
Drug: Mesalazine enteric-coated
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine enteric-coated tablets combined with placebo enema
Study: 34922383
Drug: Semaglutide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 2.0 mg
Study: 35244227
Drug: Qualitative inquiry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative inquiry into parents' experiences and preferences for ADHD treatment
Study: 35984870
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg of full spectrum extract of ashwagandha root per day for 30 days
Study: 35984870
Drug: Glycerol capsules
DrugBank: Glycerin (DB09462)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycerol capsules (placebo)
Study: 34196874
Drug: Entinostat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat (5 mg) plus Exemestane (25 mg)
Study: 34196874
Drug: Entinostat (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat (3, 5, or 7 mg/week)
Study: 34196874
Drug: Entinostat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat (5 mg)
Study: 32985088
Drug: Omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5, or 50 mg bid)
Study: 33979972
Drug: Venetoclax with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax with low-dose cytarabine (LDAC)
Study: 33979972
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with low-dose cytarabine (LDAC)
Study: 33957272
Drug: EWS +
Normalized name: Iron/Multivitamin Oral Tablet, Chewable [ZOO CHEWS + IRON]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EWS + Medication Therapy Management (MTM)
Study: 37141294
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m²
Study: 36339599
Drug: Juhongtanke oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juhongtanke oral solution (20 mL q8h for 5 days)
Study: 35710594
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy for mild chronic hypertension in pregnancy
Study: 35710594
Drug: Established antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established antihypertensive therapy during pregnancy
Study: 32725873
Drug: Low-dose NW
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose NW Roselle
Study: 32725873
Drug: High-dose NW
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose NW Roselle
Study: 35099113
Drug: Tadalafil (as-needed)
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil (as-needed) without antihypertensive medications
Study: 35099113
Drug: Tadalafil with
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil with ≥1 antihypertensive medication
Study: 35099113
Drug: Tadalafil with
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil with antihypertensive medications
Study: 34757439
Drug: Dexamethasone 12
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 12 mg daily for up to 10 days
Study: 33946565
Drug: Specific collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific collagen peptides (CP-G) 15 g daily
Study: 33946565
Drug: Placebo (P-G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P-G)
Study: 33946565
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (WP-G)
Study: 35236207
Drug: JAK inhibitors
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK inhibitors (JAKis)
Study: 34324472
Drug: 6% hetastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hetastarch in lactated electrolyte injection (HEX)
Study: 35863695
Drug: App-based mindfulness
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based mindfulness meditation intervention (MBI), delivered via smartphone app, 10 minutes twice a day for 14 days (total 280 minutes)
Study: 33957018
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of recombinant neorudin (EPR‐hirudin, EH) at doses between 0.2 and 2.0 mg/kg by intravenous bolus.
Study: 33957018
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of recombinant neorudin (EPR‐hirudin, EH) at doses of 0.15, 0.30, and 0.45 mg/kg/h.
Study: 33957018
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and continuous administration of recombinant neorudin (EPR‐hirudin, EH).
Study: 34803913
Drug: Quercetin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1 g/day)
Study: 32597691
Drug: LC09 herbal
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC09 herbal compound
Study: 35290878
Drug: Topical progesterone
Normalized name: progesterone Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical progesterone 8% ointment
Study: 35290878
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol propionate 0.05% ointment
Study: 616173498
Drug: Meldonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meldonium 1.0 g daily
Study: 616173498
Drug: Standard CHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CHF therapy
Study: 35099428
Drug: 300mg delta-tocotrienol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg delta-tocotrienol once daily for 12 weeks
Study: 33148981
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with co-amoxiclav
Study: 32303180
Drug: 6 mcg
Normalized name: ChiRhoStim 16 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mcg norepinephrine bolus
Study: 32303180
Drug: 10 mcg
Normalized name: D400, 10 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mcg norepinephrine bolus
Study: 33260468
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment phase of the behavioral weight-loss program
Study: 34477275
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (PO)
Study: 34477275
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen (IV)
Study: 35389288
Drug: Level 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 2: Level 1 plus personalized diet and exercise prescription
Study: 32898698
Drug: Ketamine-lidocaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine-lidocaine group (0.5 mg/kg ketamine plus 1 mg/kg lidocaine)
Study: 32898698
Drug: Ketamine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine group (1 mg/kg ketamine)
Study: 33894834
Drug: Sonelokimab 30
Normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonelokimab 30 mg
Study: 33894834
Drug: Sonelokimab 60
Normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonelokimab 60 mg
Study: 33894834
Drug: Sonelokimab 120
Normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonelokimab 120 mg normal load
Study: 33894834
Drug: Sonelokimab 120
Normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonelokimab 120 mg augmented load
Study: 33310293
Drug: Standard neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neoadjuvant treatment or experimental treatment modified according to interim Ki-67 evaluation
Study: 34506240
Drug: Codeine 30
Normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 30 mg/acetaminophen 325 mg every 4 hours as needed for severe pain for 4 days